Amryt’s filed Oleogel-S10 NDA for the treatment of Epidermolysis Bullosa
Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the U.S.... Read More